Nevakar
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1019 Us Hwy Route K Nj Center of Excelle...Phone Number
(908) 367-7400Website
www.nevakar.comRevenue
$20.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Nevakar
Founded in 2015 and headquartered in Bridgewater, New Jersey, Nevakar is a specialty pharmaceutical company.Explore more
Nevakar Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nevakar your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Nevakar
Nevakar, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Nevakar recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Nevakar has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Nevakar launches new products
Funding: Get notified immidiatlly once Nevakar has new funding data
Check out if Nevakar is spiking on competitors!
Click to see if Nevakar had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Nevakar
Compare insights from companies similar to Nevakar, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Nevakar is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nevakar is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nevakar.
Nevakar financials insights
Gather financial insights about Nevakar, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$55M
2020
Debt
$1M
Nevakar Tech Stack
A closer look at the technologies used by Nevakar
Most Recent Scoops
Promotion
Executive Move
Nevakar has announced that Raul Trillo has been promoted to the role of President & Chief Commercial Officer.
Left Company
Executive Move
John Peck, Vice President, Business Development, has left the organization.
Project
A mid-level source has indicated that the organization is focusing on key opinion leaders (KOP) management, market development, and clinical trial execution as part of upcoming initiatives within the marketing department.
Digital Marketing, Data Management, Workforce Management
Project
A mid-level source has indicated that initiatives related to search engine optimization (SEO) are currently in progress. The organization is focused on different market development activities before the launch. Nevakar will be leveraging a contingent workforce. Neal Wolff currently serves as Senior Director, Marketing.
Digital Marketing, Advertising, SEO / SEM, Contingent Workforce, Search
Project
Product Marketing, Advertising, Spending/Investment, Product Management
Nevakar News & Media
Vyluma Meets with FDA on Atropine Sulfate Ophthalmic Solution 0.01% Under Development to Treat Pediatric Myopia
Vyluma Discusses Response to FDA’s Questions and Clarifies Regulatory Pathway for its 505(b)(2) NDA, NVK002 to slow the progression of myopia in children.Vyluma Announces Marketing Authorization Application Validation for the European Union
Vyluma announces Marketing Authorisation Application (MAA) validation for the EU for NVK002 to slow the progression of pediatric myopia.Vyluma Announces FDA Acceptance of New Drug Application for NVK002, Its Novel Investigational Treatment for Pediatric Myopia
BRIDGEWATER, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- June 6, 2023 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead compound, NVK002 (low dose atropine 0.01%) as a potential treatment for myopia in children. NVK002 is a proprietary, investigational, preservative-free eye drop administered nightZhaoke Ophthalmology's Partner Vyluma Announces Positive Results from Phase III CHAMP Study of NVK002 for Treatment of Myopia Progression in Children
HONG KONG, Oct 28, 2022 - (ACN Newswire) - Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or "the Company", SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research, development, manufacturing and commercialization of treatments that address significant unmet medical needs, is pleased to announce that the Company's partner Vyluma, Inc. ("Vyluma") , a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced top-line res
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nevakar
Sign Up For FreeTo access detailed company insights
Founded in 2015 and headquartered in Bridgewater, New Jersey, Nevakar is a specialty pharmaceutical company.... Read More
